Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032823 · ClinicalTrials.gov registry record · Phase 3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,836
- Enrollment target
- 20
- Study locations
NCT02032823 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,836 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT02032823, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,836 participants
- Enrollment target
- 20
- Study locations
Study Summary
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olaparib
Study Locations (20)
California
- Research Site - Baldwin Park
- Research Site - Berkeley
- Research Site - Duarte
- Research Site - Fontana
- Research Site - Fresno
- Research Site - Greenbrae
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Martinez
- Research Site - Newport Beach
- Research Site - Oakland
- Research Site - Palo Alto
- Research Site - Paradise
- Research Site - Roseville
Alabama
- Research Site - Anchorage
Alaska
- Research Site - Anchorage
Arizona
- Research Site - Gilbert
Arkansas
- Research Site - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,836 participants |
| Start Date | 2014-04-22 |
| Est. Completion | 2029-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032823
The ClinicalTrials.gov registry entry for NCT02032823 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,836 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (34% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02032823 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT02032823 about?
NCT02032823 is a clinical study titled "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer". Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
What is the current status of trial NCT02032823?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,836 participants. The study started on 2014-04-22. Estimated completion is 2029-05-28.
What conditions does trial NCT02032823 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02032823?
The interventions under investigation include: Placebo (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT02032823?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02032823 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.